About
Pipeline
Investors and Media
Business Development
Contact
More
We are focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities.
Our Team
​
Our team consists of industry veterans with a proven track record of improving the lives of patients with debilitating diseases.
Our Pipeline
Our lead candidate, LX-101, is a targeted therapy for oncology and autoimmune diseases, including thyroid eye disease (TED).
Partner with Us
We are always seeking novel compounds to add to our development portfolio.
March 4, 2025
Lirum Therapeutics Presents Positive Data on LX-101 at the 2025 ESMO TAT Congress Highlighting LX-101's Promise in IGF-1R Prominent Cancers
February 8, 2023
Lirum Therapeutics announces closing of $7 million private placement of common stock
